CURRICULUM VITAE

I. PERSONAL

Name:	**Joyce Marie Slingerland, MD, PhD, FRCP(C)**
Office Phone:	(305) 243-7265
Current Academic Rank:	Professor
Current Track of Appointment:	Tenured
Primary Department:	Medicine Division of Hematology/Oncology University of Miami Miller School of Medicine
Secondary Appointment:	Department of Biochemistry and Molecular Biology Graduate Cross Appointment
Citizenship:	American and Canadian

II. HIGHER EDUCATION

Institutional

- University of Toronto, Department of Molecular and Medical Genetics, Dr. B.J. Andrews, Postdoctoral Fellowship, 1993-1994
- The Scripps Research Institute, Department of Molecular Biology, Dr. Steven I. Reed, Postdoctoral Fellowship, 1992-1993
- University of Toronto, Department of Medical Biophysics, PhD, November 1992
- University of Toronto, Department of Medical Biophysics (Biology Stream), Dr. S. Benchimol, PhD Student, September 1988 – November 1992
- Princess Margaret Hospital, Division of Oncology, Clinical Research Fellow, July 1987 – June 1988
- The Wellesley Hospital, Chief Medical Resident, July 1986 – June 1987
- Princess Margaret Hospital, Medical Oncology Resident, July 1985 – June 1986
- Toronto Hospital (General Division), Resident II, Internal Medicine, July 1984 – June 1985
- Toronto Hospital (General Division), Internal Medicine, Straight Internship, July 1983 – June 1984
- University of Toronto, MD, June 1983
- College de Ste-Foy, Diplome d'Etudes Collegiales, June 1977

Certification, Licensure

- Member of AMA (American Medical Association), 2006 – 2007
- Medical Licensure: State of Florida #ME89246, December 2003
- Certificate of Special Competence in Medical Oncology, The Royal College of Physicians and Surgeons of Canada, September 1988
- American Board Certification in Internal Medicine, September 1987
- FRCP(C), Fellowship in Internal Medicine, Fellow of the Royal College of Physicians and Surgeons of Canada, June 1987
- Medical Licensure: Ontario College of Physicians and Surgeons, Ontario, Canada, August 1984 to present
- Licentiate of the Medical Council of Canada, June 1983

III. EXPERIENCE

Academic

- UM Sylvester Comprehensive Cancer Center, Associate Director for Translational Research, January 2010 – present
- UM Sylvester Comprehensive Cancer Center, Breast Cancer Program Leader, September 2008 – present
- UM Sylvester Comprehensive Cancer Center, Breast Cancer Theme Leader, Molecular Targets and Developing Therapeutics Program (formerly MOET), July 2005 – September 2008
- UM Sylvester Comprehensive Cancer Center, Molecular Oncology and Experimental Therapeutics (MOET) Program Leader, July 2005 – June 2007
- UM Sylvester Comprehensive Cancer Center, Director, Braman Family Breast Cancer Institute, September 2002 – present
- University of Miami, Miller School of Medicine, Department of Medicine, Division of Hematology/Oncology, Professor of Medicine with Tenure, July 2003 – present
- University of Miami, Miller School of Medicine, Department of Biochemistry and Molecular Biology Graduate Cross Appointment, September 2002 – present
- University of Miami, Miller School of Medicine, Department of Medicine, Division of Hematology/Oncology, recommended for appointment as Professor of Medicine, September 2002
- University of Toronto, School of Graduate Studies, Adjunct Member, Department of Medical Biophysics, August 2002 – present

- University of Toronto, Department of Medicine, Associate Professor, July 1999 – September 2002
- University of Toronto, School of Graduate Studies, Full Member, Department of Medical Biophysics, September 1994 – August 2002
- University of Toronto, School of Graduate Studies, Full Member, Institute of Medical Sciences, July 1995 – August 2002
- Sunnybrook Health Science Centre, Division of Cancer Biology Research, Senior Scientist, July 1994 – August 2002
- Toronto-Sunnybrook Regional Cancer Centre, Division of Medical Oncology, Staff, July 1993 – August 2002
- University of Toronto, Department of Medicine, Assistant Professor, July 1993 – June 1999

Hospital Appointments

- Jackson Memorial Hospital, Attending Physician, October 2002 – present
- VA Medical Center, Attending Physician, October 2002 – present
- University of Miami Hospital and Clinics, Attending Physician, October 2002 – present
- UM Sylvester Comprehensive Cancer Center, Breast Site Disease Group Leader, October 2002 – January 2004
- Associate Director, Taylor Breast Health Center, Jackson Memorial Hospital, 2002 – 2006

IV. PUBLICATIONS

Books and Monographs

1. Sun J, Zhou W, Nawaz Z, **Slingerland JM.** (2011) Cross Talk between ERα and Src signaling and its relevance to ER status and hormone responsiveness. Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. Editors: G. Castoria & A. Migliaccio, Springer, New York, pp. 61-78.

2. Donovan J, **Slingerland JM**, Tannock I. (2004) Control of cell proliferation. In: 4rd Edition of Basic Science of Oncology. Editors: Ian Tannock and R.P. Hill, McGraw-Hill, New York, Chapter 10.

3. **Slingerland JM**, Tannock I. (1998) Control of cell proliferation and cell death. In: 3rd Edition of Basic Science of Oncology. Editors: Ian Tannock and R.P. Hill, McGraw-Hill, New York, Chapter 7, pp. 134-165.

4. **Slingerland JM**, Pagano M. (1998) Regulation of the cell cycle by the ubiquitin pathway. In: Cell Cycle Control. Part of the results and problems in cell differentiation series. Springer Verlag Publishers (Editor: M. Pagano), Chapter 6, pp. 133-147.

5. **Slingerland JM**, Greisser H, Mak TW, Minden MD. (1988) The structure and function of the T-cell antigen receptor in human malignancies. In: T.W. Mak (Ed.), The T-cell Receptor, New York: Plenum Press.

Refereed Journal Articles

Manuscripts in Preparation/in Review

1. Zhao D, Besser A, Wander S, Sun J, Wang B, Ince T, Zhou W, Guo W, Mills G, Theodorescu D, and Slingerland J. (2014) Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene in revision

2. Simpkins F, Hew K, Zhao D, Jang K, Mills G, Ince T and **Slingerland JM.** (2014) Targeting MEK and Src to target ovarian cancer stem cells and tumor growth- for submission to Science Translational Medicine

3. Hew K, Miller P, El-Ashry D, Sun J, Guo W, Zhang G, Gao W, Lu Y, Brafford P, Mills G., Ince T, Slingerland JM, Simpkins F.(2014) MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/Estrogen regulated gene and protein expression For submission to Clinical Cancer Research

4. Sun J, Nawaz Z, and **Slingerland JM.** (2014) Src drives estrogen activated CXCL12 induction to promote cancer stem cell self-renewal and tumor metastasis- For submission to PNAS.

5. Pan C, Drews-Elger K, Zhao D, Besser A, Kim M, Ince TA, Azzam D, Picon-Ruiz M, Wander SA, Wang B, Ergonul B, Datar R, Cote R, Howard GA, El-Ashry D, **Slingerland JM.** (2014) Adipocyte-breast cancer contact upregulates cytokines that drive tumor progression. For submission to Cancer Research

6. Friedman E, Hurley J, Reis E, and Slingerland JM. (2014) Obesity and breast cancer outcome: analysis of BMI and neoadjuvant therapy outcome in a cohort of Hispanic and African American breast cancer patients treated for locally advanced breast cancer. - for submission to Breast Cancer Research and Treatment.

Published

1. Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Ullmer W, Howard G, Ince T, Creighton C, **Slingerland JM**. (2014) Adipocyte-cancer cell contact drives cancer initiating cells via VEGF-dependent upregulation of Myc and Sox2. *Oncogene*- in press.

2. Zhou W, **Slingerland JM.** Links between steroid receptor activation and proteolysis: potential relevance to therapy of hormone regulated cancers. (2014) ***Nature Reviews Cancer*** 2014; 14: 26-38

3. Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, **Slingerland JM**, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Res Treat 2014; 144(3):503-17. PMID: 24567196.

4. Azzam D, Drews-Elger K, Zhao D, Picon-Ruiz M, Ranganathan P, Han X, Sun J, Minn AJ, Creighton CJ, Pan C, Wander SA, Capobianco AJ, El-Ashry D, **Slingerland JM.** (2013) $CD44^{+}CD24^{low+}$ progenitors in ER negative breast cancer generate $CD44^{+}CD24^{neg}$ cells, and show increased Notch1-mediated Sox2 activation, increased self-renewal and greater metastatic potential. *EMBO Molecular Medicine* 5: 1–21. July16. DOI 10.1002/emmm.201302558 (Collaboration, 80% effort from my lab)

5. Zhou W, Sun J, Srinivasan S, Nawaz Z, **Slingerland JM**. (2013) ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression. *Oncogene* 2014 May 1;33(18):2341-53. (Collaboration, 90% effort from my lab)

6. Simpkins F, Garcia-Soto A, **Slingerland JM.** (2013) New insights on the role of hormonal therapy in ovarian cancer. *Steroids* 78(6):530-7.

7. Gilbert CA, **Slingerland JM.** (2013) Cytokines, obesity and cancer: new insights on mechanisms linking obesity to cancer risk and progression. *Annu Rev Med* 64:45-57.

8. Wander S, Zhao D, Besser A, Hong F, Wei J-Q, Ince T, Milikowski C, Bishopric N, Minn A, Creighton C, and **Slingerland JM**. (2013) PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. *Breast Cancer Res Treat* 138(2):369-81. (Collaboration, 95% effort from my lab)

9. Simpkins F, Hevia-Perez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu X, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, **Slingerland JM.** (2012) Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. *Clin Cancer Res* 18(21):5911-23. (Collaboration, 95% effort from my lab)

10. Sun J, Zhou W, Kaliappan K, Nawaz Z, **Slingerland JM.** (2012) ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. *Mol Endocrinol* 26(9):1567-77. (Collaboration, 100% effort from my lab)

11. Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, **Slingerland JM**, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S. (2012) Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. *Breast Cancer Res Treat* 132(1):215-23.

12. Wen S, So Y, Zhang S, Ruiz V, Singh K, Resnick M, **Slingerland JM**, Moss SF. (2012) Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer. *Oncogene* 31(14):1771-80. (Collaboration, 10% effort from my lab)

13. Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Desire L, **Slingerland JM**, Burnstein KL. (2011) Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. *Endocr Relat Cancer* 18(2):207-19. (Collaboration, 10% effort from my lab)

14. Hammes, SR, Kelly MJ, **Slingerland JM.** (2011) The physiology of integrated nuclear and extranuclear steroid signaling: Introductory comments. *Steroids* 76(9):821.

15. Wander SA, Hennessy B, **Slingerland JM.** (2011) Next generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. *J Clin Invest* 121(4):1231-41.

16. Wander SA, Zhao D, **Slingerland JM.** (2011) p27: A barometer of signaling deregulation and potential predictor of response to targeted therapies. *Clin Can Res* 17(1):12-18.

17. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, Ju Z, Hennessy BT, **Slingerland JM.** (2011) Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. *Breast Cancer Res Treat* 128(1):69-78. (Collaboration, 90% effort from my lab)

18. Liao J, Gallas M, Pegram M, **Slingerland JM.** (2010) Lapatinib: new opportunities for management of breast cancer. *Breast Cancer: Targets and Therapy* 2:93-109.

19. Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, Hurley E, Hurley J, Reis I, Richman S, Seo P, Silva O, **Slingerland JM**, Tukia K, Welsh C, Glück S. (2010) Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer (MBC). *Breast Cancer Res Treat* 123(2):427-35.

20. Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, DeBoer GE, Sutherland DJA, Emmenegger U, **Slingerland JM**, Gardner S, Pritchard KI. (2009) Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate and daily prednisone (DalCMP) as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. *J Clin Oncol* 28(5):723-30**.**

21. Larrea M, Hong F, da Silva TG, Wander S, Lannigan D, Smith JA, Helfman D, **Slingerland JM.** (2009) RSK1 drives $p27^{Kip1}$ phosphorylation at T198 to promote RhoA inhibition and increase cell motility. *Proc Natl Acad Sci USA* 106(23):9268-73. (Collaboration, >90% effort from my lab)

22. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, **Slingerland JM.** (2009) Combined Src and aromatase inhibition impairs human breast cancer growth *in vivo* and bypass pathways are activated in AZD0530 resistant tumors. *Clin Cancer Res* 15(10):3396-405. (Collaboration, >90% effort from my lab)

23. Larrea MD, Wander SA, **Slingerland JM.** (2009) p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. *Cell Cycle* 8(21):3455-61.

24. Chu I, Hengst L, **Slingerland JM.** (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. *Nature Reviews Cancer* 8(4):253-67.

25. Larrea M, Liang J, Hong F, da Silva T, Shao SH, Han K, Dumont D, **Slingerland JM**. (2008) Phosphorylation of $p27^{Kip1}$ regulates assembly and activation of cyclin D1-Cdk4. *Mol Cell Biol* 28(20):6462-72. (100% effort)

26. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, **Slingerland JM.** (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. *Molecular Cell* 30(6):701-11. (Collaboration, 90% effort from my lab)

27. Silva O, Lopes G, Morgenzstern D, Lobo C, Doliny P, Santos E, Abdullah S, Gautam U, Reis I, Welsh C, **Slingerland JM**, Hurley J, Glück S. (2008) A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2-negative metastatic breast cancer. *Clin Breast Cancer* 8(2):162-7.

28. Sun J, Nawaz Z, **Slingerland JM.** (2007) Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in human breast cancer cells. *Mol Endocrinol* 21(11):2651-62. (Collaboration, 100% effort from my lab)

29. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon Ch, Chun K, Hennessy B, Mills GB, Nawaz Z, **Slingerland JM.** (2007) Src promotes estrogen-dependent ERα proteolysis in human breast cancer. *J Clin Invest* 117(8):2205-15. (Collaboration, 90% effort

from my lab)

30. Govindarajan B, Sligh J, Vincent B, Li M, Canter J, Nickoloff, BJ, Rodenburg RJ, Smeitink, JA, Oberley L, Zhang Y, **Slingerland JM**, Arnold RS, Lambeth JD, Cohen C, Hilenski L, Greindling K, Martinez-Diez M, Cuezva JM, Arbiser JL. (2007) Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. *J Clin Invest* 117(3):719-29. (Collaboration)

31. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, **Slingerland JM.** (2007) p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. *Cell* 128(2):281-94. (Collaboration, 90% effort from my lab)

32. Liang J, Shao SH, Xu Z, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, **Slingerland JM**, Mills GB. (2007) The energy sensing LKB1-AMPK pathway regulates $p27^{Kip1}$ phosphorylation mediating the decision to enter autophagy or apoptosis. *Nat Cell Biol* 9(2):218-24. (Collaboration, 20% effort)

33. Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, **Slingerland JM**, O'Malley BW, Nawaz Z. (2006) WW-domain binding protein-2, an E6-associated protein, acts as a coactivator of estrogen and progesterone receptors. *Mol Endocrinol* 20(10):2343-54.

34. Esserman LJ, Ozanne EM, Dowsett M, **Slingerland JM.** (2005) Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. *Breast Cancer Res* 7(6):R1154-8. (Collaboration, 50% effort)

35. Chu I, Blackwell K, Chen S, **Slingerland JM.** (2005) The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with Tamoxifen to inhibit both cell proliferation and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. *Cancer Res* 65(1):18-25. (Collaboration, 70% effort from my lab)

36. Sandhu C, Connor M, Kislinger T, **Slingerland JM**, Emili A. (2005) Global protein shotgun expression profiling of proliferating MCF-7 breast cancer cells. *J Proteome Res* 4(3):674-89.

37. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, **Slingerland JM**, Dumont D, Yang BB. (2005) The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. *Mol Biol Cell* 16(3):1330-40. (Collaboration, 20% effort)

38. Alkarain A, Jordan R, **Slingerland JM.** (2004) p27 deregulation in breast cancer: prognostic significance and implications for therapy. *J Mammary Gland Biol Neoplasia* 9(1):67-80.

39. Arnaout A, **Slingerland JM.** (2003) Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. *Breast Cancer Res* 6(1):13-21. Epub 2003 Oct 21.

40. Liang J, **Slingerland JM.** (2003) Multiple roles of the P13K/PKB (Akt) pathway in cell cycle progression. *Cell Cycle* 2(4):339-45.

41. Connor M, Kotchetkov R, Carious S, Resch A, Lupetti R, Beniston R, Melchior F, Hengst L, **Slingerland JM.** (2003) CRM1/Ran-mediated nuclear export of $p27^{Kip1}$ involves a nuclear export signal and links p27 export and proteolysis. *Mol Biol Cell* 14(1):201-13. (Corresponding author, 90% in my lab)

42. Donovan JCH, Rothenstein J, **Slingerland JM.** (2002) Non-malignant and tumor-derived cells differ in their requirement for $p27^{Kip1}$ in transforming growth factor-β G1 arrest. *J Biol Chem* 277(44):41686-92. (Corresponding author, 100% effort)

43. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, **Slingerland JM.** (2002) PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. *Nat Med* 8(10):1153-60. (Corresponding author, 100% effort my lab

44. Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, Milic A, **Slingerland JM.** (2002) Altered $p27^{kip1}$ phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor-β mediated G1 arrest. *Mol Cell Biol* 22(9):2993-3002. (Corresponding author, 100% effort from my lab)

45. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, **Slingerland J**, Krek W. (2001) Skp2 is oncogenic and overexpressed in human cancers. *Proc Natl Acad Sci USA* 98(9):5043-8. Epub 2001 Apr 17. (Co-corresponding author, 50% effort my lab)

46. Donovan JC, Milic A, **Slingerland JM.** (2001) Constitutive MEK/MAPK activation leads to $p27^{Kip1}$ deregulation and antiestrogen resistance in human breast cancer cells. *J Biol Chem* 276(44):40888-95. Epub 2001 Aug 29. (Corresponding author, 100% effort)

47. Petrocelli T, **Slingerland JM.** (2001) PTEN deficiency: a role in mammary carcinogenesis. *Breast Cancer Res* 3(6):356-60. (Corresponding author, 100% effort)

48. Sandhu C, **Slingerland JM.** (2000) Deregulation of the cell cycle in cancer. *Cancer Detect Prev* 24(2):107-18.

49. **Slingerland JM**, Pagano, M. (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. *J Cell Physiol* 183(1):10-17.

50. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, **Slingerland JM**. (2000) Involvement of $p27^{Kip1}$ in G1 arrest by high dose 5α-dihydrotestosterone in LNCaP human prostate cancer cells. *Oncogene* 19(5):670-9. (Corresponding author, 100% effort from my lab)

51. Sandhu C, Peehl D, **Slingerland JM.** (2000) p16INK4A mediates cyclin-dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. *Cancer Res* 60(10):2616-22. (Corresponding author, Collaboration, 90% effort from my lab)

52. Tamir A, Petrocelli T, Stetler K, Chu W, Howard J, St Croix B, **Slingerland JM**, Ben-David Y. (2000) Stem cell factor inhibits erythroid differentiation by modulating the activity of G1-cyclin-dependent kinase complexes: A role for p27 in erythroid differentiation coupled G1 arrest. *Cell Growth Differ* 11(5):269-77. (Collaboration, 50% effort from my lab, my student is the co-first author)

53. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, **Slingerland JM.** (2000) Down-regulation of $p21^{WAF1/CIP1}$ or $p27^{Kip1}$ abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. *Proc Natl Acad Sci USA* 97(16):9042-6. (Corresponding author, 100% effort in my lab)

54. Petrocelli T, **Slingerland JM.** (2000) UVB induced cell cycle checkpoints in an early stage human melanoma line, WM35. *Oncogene* 19(39):4480-90. (Corresponding author, 100% effort in my lab)

55. Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, **Slingerland JM**, Foulkes WD. (2000) Germline BRCA1/2 mutations and $p27^{Kip1}$ protein levels independently predict outcome after breast cancer. *J Clin Oncol* 18(24):4045-52. (Collaborator, 50% effort in my lab)

56. Sandhu C, Donovan J, Bhattacharya N, Stampfer M, Worland P, **Slingerland JM.** (2000) Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. *Oncogene* 19(47):5314-23. (Corresponding author, 100% effort in my lab)

57. Donovan J, **Slingerland JM.** (2000) Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. *Breast Cancer Res* 2(2):116-124. Epub 2000 Feb 21.

58. **Slingerland JM.** (2000) Transforming growth factor-beta and breast cancer. *Breast Cancer Res* 2(2):91. Epub 2000 Feb 21.

59. Tshilias J, Kapusta L, **Slingerland JM.** (1999) The prognostic significance of altered cyclin-dependent kinase inhibitors. *Annu Rev Med* 50:401-23.

60. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, **Slingerland JM**, Kerbel RS. (1999) Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor $p21^{WAF1/CIP1}$ is lost during progression of human malignant melanoma. *Oncogene* 18(4):1023-32. (Co-correspondent, collaboration 70% effort from my lab)

61. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, **Slingerland JM.** (1999). Reduced expression of the cell cycle inhibitor $p27^{Kip1}$ in non-small cell lung

carcinoma: a potential prognostic factor independent of *ras*. *Cancer Res* 59(3):684-8. (Corresponding author, 80% effort from my laboratory)

62. Tsihlias J, Kapusta LR., DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, **Slingerland JM.** (1998) Loss of cyclin-dependent kinase inhibitor $p27^{Kip1}$ is a novel prognostic factor in localized human prostate adenocarcinoma. *Cancer Res* 58(3):542-8. (100% effort from my laboratory)

63. Jordan R, Bradley G, **Slingerland JM.** (1998) Reduced levels of the cell-cycle inhibitor $p27^{Kip1}$ in epithelial dysplasia and carcinoma of the oral cavity. *Am J Pathol* 152(2):585-90. (Collaborator, 10% effort from my laboratory)

64. St Croix B, Sheehan C, Rak J, Florenes VA, **Slingerland JM**, Kerbel RS. (1998) E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor $p27^{Kip1}$. *J Cell Biol* 142(2):557-71. (Collaborator, 20% effort from my lab)

65. Zhang W, Kapusta LR, Klotz LH, **Slingerland JM.** (1998) Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. *Cancer Res* 58(4):619-21. (Collaborator, 50% effort from my lab)

66. Florenes VA, Maelandsmo GM, Kerbel RS, **Slingerland JM**, Nesland JM, Holm R. (1998) Protein expression of the cell-cycle inhibitor $p27^{Kip1}$ in malignant melanoma: inverse correlation with disease-free survival. *Amer J Path* 153(1):305-12. (Collaborator, 50% effort from my lab)

67. Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, **Slingerland JM**, Amati B. (1998) Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. *Oncogene* 17(20):2637-43. (Collaborator, 40% effort from my lab)

68. Cariou S, Catzavelos C, **Slingerland JM.** (1998) Prognostic implications of expression of the cell-cycle inhibitor protein p27Kip1. *Breast Cancer Res Treat* 52(1):29-41. (Special issue on prognostic variables in node-negative and node-positive breast cancer)

69. **Slingerland JM,** Pagano M. (1998) Regulation of the cell cycle by the ubiquitin pathway. *Results Probl Cell Differ* 22:133-47.

70. Catzavelos C, Bhattacharya N, Wilson J, Sandhu C, Roncari L, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Ung Y, **Slingerland JM.** (1997) Decreased levels of the cell cycle inhibitor $p27^{Kip1}$ protein: prognostic implications in primary breast cancer. *Nat Med* 3(2):227-30. (Corresponding author, 100% effort, project generated in my lab)

71. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, **Slingerland JM**, Stampfer MR. (1997) TGF-β stabilizes $p15^{INK4B}$ protein, increases $p15^{INK4B}$/cdk4 complexes, and inhibits cyclin D1/cdk4 association in human mammary epithelial cells. *Mol Cell Biol* 17(5):2458-67. (Corresponding author, collaboration, 90% effort from my lab)

72. Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, **Slingerland JM**, Dedhar S. (1997) Overexpression of the Integrin Linked Kinase (ILK) promotes anchorage-independent cell cycle progression. *J Biol Chem* 272(21):13937-44. (Collaboration, 30% effort from my laboratory)

73. LaBaer J, Garrett M, Stevenson L, **Slingerland JM**, Sandhu C, Chou H, Fattaey A, Harlow E. (1997) New functional activities for the p21 family of CDK inhibitors. *Genes Dev* 11(7):847-62. (Collaboration, 20% effort from my laboratory)

74. **Slingerland JM.** (1997) Cancer Therapeutics: experimental and clinical agents. Edited by Beverly A. Teicher. Book Review. *Nat Med* 3(5):581-2.

75. Petrocelli T, Poon R, Drucker DJ, **Slingerland JM**, and Rosen CF. (1996) UVB radiation induces $p21^{Cip1/WAF1}$ and mediates G1 and S phase checkpoints. *Oncogene* 12(7):1387-96. (Corresponding author; collaboration with Rosen lab, 70% effort from my lab)

76. Florenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, **Slingerland JM.** (1996) TGF-β mediated G1 arrest in a human melanoma cell line lacking $p15^{INK4B}$: evidence for cooperation between $p21^{Cip1/WAF1}$ and $p27^{Kip1}$. *Oncogene* 13(11):2447-57. (Corresponding author; 100 % effort from my laboratory)

77. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, **Slingerland JM**, Kerbel RS. (1996) Impact of the cyclin dependent kinase inhibitor $p27^{Kip1}$ on adhesion-dependent resistance of tumor cells to anticancer agents. *Nat Med* 2(11):1204-10. (Collaboration, 20% effort from my lab)

78. Liu L, Lassam NJ, **Slingerland JM**, Bailey D, Cole D, Jenkins R, Hogg D. (1995) Germline $p16^{INK4A}$ mutation and protein dysfunction in a family with inherited melanoma. *Oncogene* 11(2):405-12. (Collaborator, 20% effort from my laboratory)

79. Reed SI, Bailly E, Bulic V, Hengst L, Resnitzky D**, Slingerland JM.** (1994) G1 control in mammalian cells. *J Cell Sci Suppl* 18:69-73.

80. **Slingerland JM**, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. (1994) A novel inhibitor of cyclin/cdk activity detected in TGF-β arrested epithelial cells. *Mol Cell Biol* 14(6):3683-94. (Principal author, 100% effort)

81. Hengst L, Dulic V, **Slingerland JM**, Lees E, Reed SI. (1994) A cell cycle-regulated inhibitor of cyclin-dependent kinases. *Proc Natl Acad Sci USA* 91(12):5291-5. (Collaborator, 30% effort)

82. Lishner M, **Slingerland JM**, Theresa C, Sutcliffe SB. (1994) The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy. *Leuk Lymphoma* 13(1-2):131-6. (Collaboration, 50% effort)

83. **Slingerland JM**, Jenkins JR, Benchimol S. (1993) The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization, and nuclear translocation. *EMBO J* 12(3):1029-37. (Principal author, 100% effort)

84. **Slingerland JM**, Minden M.D., Benchimol S. (1991) Mutation of the p53 gene in human acute myelogenous leukemia. *Blood* 77(7):1500-7. (Principal author, 100% effort)

85. Lishner M, **Slingerland JM**, Barri J, Panzarella T, Degendorfer P, Sutcliffe S. (1991) Second malignant neoplasms in patients with non-Hodgkin's lymphoma. *Hematol Oncol* 9(3):169-79. (Collaborator, 50% effort)

86. **Slingerland JM**, Benchimol S. (1991) Transforming activity of mutant human p53 alleles. *J Cell Physiol* 148(3):391-5. (Principal author, 100% effort)

87. **Slingerland JM**, Grossman R, Chamberlain D, Tremblay C, Gauthier ML. (1989) Pulmonary manifestations of tuberous sclerosis in first degree relatives. *Thorax* 44(3):212-4. (Principal author, 100% effort)

88. Tiberius RG, Sackin HD, **Slingerland JM**, Jubas K, Bell M, Matlow A. (1989) The influence of student evaluative feedback on the improvement of clinical teaching. *J Higher Ed* 60(6):665-81. (Collaborator, 20% effort)

V. PROFESSIONAL

Funded Research

Operating and Career Award Grants – Active

Breast Cancer Research Foundation **2004-2015**
Characterization of mammary progenitor cells and how contact with adipocytes affects normal and malignant human mammary epithelial progenitor cell populations
(PI)
$240,000/yr
Indefinite renewal

Doris Duke Charitable Foundation Distinguished Clinical Scientist Translational Research Award **2007-2014**
Molecular therapies for hormone resistant breast cancer
(PI)
$312,621/yr
No cost extension

UM607 Florida Department of Health **2008-2014**
Braman Family Breast Cancer Institute Developmental Grants Program $96,000/yr
Funds a Developmental Grants Program directed by the PI to provide seed funding for two new breast cancer research projects/yr.
(PI)

NIH-NCI 1-R01-CA-123415-01A2 **2009-2014**
Mechanisms whereby Src activates estrogen stimulated ER proteolysis $298,826/yr
and ER target to JMS lab
(Co-PI with Z. Nawaz)

NIH-NCI 1-R21-CA-133884-02 **2009-2014**
A Neoadjuvant Trial of Anastrozole and a Novel Src Inhibitor, AZD0530, $207,500
for LABC
(PI)

NIH-NCI 5-R01-CA-105118-04 **2010-2015**
Effects of the PI3K pathway on p27 function and cancer progression $309,122/yr
(PI)

Operating and Career Award Grants Received – Completed

American Federation for Clinical Research Foundation Early Career Development Award **1995-1998** (US funds)
$20,000/yr
Mechanisms of resistance to growth arrest by TGF-β in human epithelial cancer 100% direct
(PI, 100% effort)

Canadian Breast Cancer Research Initiative, **NCIC** **1996-1999** (CDN funds)
The roles of $p15^{INK4B}$ and $p27^{Kip1}$ in resistance to growth inhibition by $84,360/yr
TGF-β in human mammary epithelial cells and in breast cancer (PI, 100% direct
100% effort)

Ontario Cancer Institute, NCIC/ CCS – Molecular Epidemiology Extension **1997-1998** (CDN funds)
$32,760
Lung cancer molecular pathology and tumor bank 100% direct
(PI: Dr. Ming Tsao; Co-PIs: F. Shepherd, D. Chamberlain, J. Slingerland – my effort 10%)

Canadian Breast Cancer Research Initiative, **NCIC** **1997-1999** (CDN funds)
Evaluation of the cell cycle inhibitor $p27^{Kip1}$ as a prognostic factor in $137,077/1st year;
node negative breast cancer $60,744/2nd year
(PI; Co-applicants: C. Catzavelos, I. Andrulis, S. Bull, W. Hanna – my 100% direct
effort 40%)

Canadian Breast Cancer Foundation **1997-1998** (CDN funds)
A comparison of immunostaining of phosphorylated erbB-2 and erbB-2 gene amplification as prognostic markers in node negative breast cancer (PI, 100% effort) $50,000
100% direct

National Cancer Institute of Canada **1998-2000** (CDN funds)
Prognostic factors for metastatic progression of localized prostate cancer (PI: S.A. Narod; Co-PIs: R. Nam, M. Pollak, L. Klotz, J. Sweet, J. Slingerland, E. Diamandis, my effort 10%) $132, 449/1st year, $18,730/2nd year
100% direct

DOD Prostate Cancer Research Program – US Army **1998-2000** (US funds)
The cell cycle inhibitor $p27^{Kip1}$: A key mediator of G1 arrest by androgen ablation and by vitamin D3 analogs
(PI) $74,996/yr
100% direct

DOD Breast Cancer Research Program – US Army **1998-2001** (US funds)
Resistance to tamoxifen: A consequence of altered $p27^{Kip1}$ regulation during breast cancer progression?
(Idea Award, PI) $38,557/yr direct
$12,194/yr indirect (30%)
$50,751/yr Total

DOD Breast Cancer Research Program – US Army **1998-2002** (US funds)
Resistance to tamoxifen: A consequence of altered $p27^{Kip1}$ regulation during breast cancer progression?
(Career Development Award, PI) $50,000/yr direct
$15,000/yr indirect (30%)
$65,000/yr Total

Burroughs Wellcome Fund 1998 Clinical Scientist Award in Translational Research **1998-2003** (US funds)
Resistance to tamoxifen: A consequence of altered p27Kip1 regulation during breast cancer progression
(PI) $150,000/yr.
100% direct

Canadian Breast Cancer Research Initiative, NCIC **1999-2002** (CDN funds)
Altered signal transduction and p27 regulation of TGF-β resistant mammary epithelial cells and breast cancer
(PI, 100% effort) $126,804/yr
100% direct

Canada Foundation for Innovation **2001-2004** (CDN funds)
Sunnybrook & Women's College Comprehensive Multi-disciplinary Breast Cancer Centre: Provides infrastructure support for new breast cancer research centre
(PIs: K. Pritchard, M. Yaffe; Co-PI: J.M. Slingerland – my effort and writing of this grant was 30%) $11.25 million (in total) over 3 years
100% direct

Canada Research Chair Tier II **2001-2006** (CDN funds)
Breast cancer and molecular biology research $100,000/yr
(PI – Salary Support) 100% direct

Canada Foundation for Innovation, *(with OIT & SWCHSC)* **2001-2006** (CDN funds)
Breast cancer and molecular biology research $315,500 Total
(PI – Infrastructure Equipment Grant) 100% direct

National Cancer Institute of Canada **2002-2007** (CDN funds)
Mechanisms of resistance to G1 arrest by TGF-β $149,975/yr
(PI; renewal of grant #11; Canadian NCIC operating grants have a ceiling of 150,000/yr; not transferable to US on move in 2002) 100% direct

J&J R115777INT22 **2003-2004**
A randomized, blinded, Phase II study of letrozole plus the farnesyl transferase inhibitor ZARNESTRA (R115777) and letrozole plus placebo in the treatment of advanced breast cancer after antiestrogen therapy $37,461/yr
(Principal Investigator) 100% direct

NIH-NCI 5-R01-CA-107705-03 **2004-2008**
Vitamin D promotes G1 arrest via CDK2 mislocalization
(PI: K. Burnstein; Co-PI: J. Slingerland)

NIH-NCI 5-R01-CA-105118-04 **2004-2008**
P13K opposes p27 and G1 arrest by TGF-β in human cancer $164,000/yr direct
(Principal Investigator)

Pfizer, Inc. PD325901 **2005-2007**
Use of the MEK inhibitor PD325901 to abrogate antiestrogen resistance in human breast cancer $ 49,220/yr direct
(Principal Investigator)

Florida State Department of Health UM47701 **2005-2007**
Braman Breast Cancer Institute Infrastructure award $2,500,000 total

Department of Defense (DOD) Historically Black and Minority Institution Partnership Training Award **2006-2010**
Identification of the oxidative stress mechanisms underlying antiestrogen resistance $250,000/yr total
FIU-UMSCCC Braman Family Breast Cancer Institute Partnership
(PI: D. Roy; Co-PI: J. Slingerland)

Flight Attendants Medical Research Institute **2007-2010**
Targeting the Src oncogene in breast cancer therapy $100,000/yr direct
(Principal Investigator)

Bankhead Coley Breast SPORE Planning Grant (PI) **2009-2012**
Novel Experimental Therapeutic Approaches to Breast Cancer Therapy Total $500,000/yr
Use of MEK and Src inhibitors with fulvestrant in ER negative breast cancer (PI Project 1) $99,000/yr to PI Project 1

Florida Breast Cancer Foundation (FBCF) Fellowship Grant 2008-2012
Braman Family Breast Cancer Institute Breast Cancer Clinical Research Fellowships- funds a clinical research fellowship program Directed by the PI to support post-subspecialty training of oncology trainees in clinical research in Breast Pathology, Imaging, Familial Genetics, Med, Rad or Surg Oncology of breast cancer Total $100,000/yr
(Director)

NIH-NCI 1-T32-CA119929-01A1 Training Grant (NCE) 2007-2012
Post-doctoral Fellowship training in translational breast cancer research **$344,801/yr**
(PI)

Pre- and Post-doctoral Fellowship Awards and Studentship Support

Sandrine Cariou
Department of Medicine, Postgraduate Award **1997-1998**
University of Toronto $20,000/yr ($CDN)

John Tshilias
National Cancer Institute of Canada **1997-2000**
Terry Fox Research Fellowship $45,400/yr ($CDN)

Michael Connor
Sunnybrook Trust Award **1999–2000**
$32,000 ($CDN)
DOD US Army Breast Cancer Post-doctoral Fellowship **2002-2005**
$50,000/yr ($US)

Yi Chen
Avon Foundation AACR **2006-2008**
International Scholar Award in Breast Cancer Research $79,400/yr direct
Molecular targeted therapies to reverse antiestrogen resistance in breast cancer

Pre-doctoral Fellowship Awards

Jeffrey Donovan
DOD US Army Breast Cancer Pre-doctoral Fellowship **2000-2003**
$21,893/yr ($US)

Jiyong Liang
Ontario Graduate Studies Award
1999–2000
DOD US Army Breast Cancer Research Program Pre-doctoral 19,500 ($CDN)
Fellowship **2001-2004**
26,000/yr ($US)

Isabel Chu
Ontario Graduate Studies Award **2001**
$24,000 *(declined)*
University of Toronto Medical Oncology Award **2001**
$28,000 ($CDN)
Department of Defense Breast Cancer Research Program **2004-2007**
W81XWH-04-1-0392 $30,000/yr direct
cSRC and Her2 signaling pathways cooperate with estrogen to promote ER phosphorylation, ubiquitination and proteolysis in ER negative breast cancers

Michelle Larrea
NIH-NCI Pre-Doctoral Fellowship – Minority Students **2004-2008**
NIH-NCI – 1-F31-CA-113284-01 $34,152/yr direct
Involvement of p90-RSK in the deregulation of p27

Thiago da Silva
Department of Defense Breast Cancer Research Program **2005-2009**
W81XWH-06-1-0754 $30,000/yr direct
Pre-doctoral Award
CDK2 Phosphorylation in Threonine39 by AKT and its Implication on Cyclin Binding, Cellular Localization and Cell Cycle Progression

Wen Zhou
Department of Defense Breast Cancer Research Program **2011-2014**
W81XWH-11-1-0097 $38,886/yr direct
Pre-doctoral Award
The Role of Skp1-Cul1-F-box Ubiquitin Ligases in Src-Stimulated Estrogen Receptor Proteolysis and Estrogen Receptor Target Gene Expression

Fiona Simpkins
NIH Clinical Investigator Award **2011-2016**

1K08CA151892-01A1 $161,408/ yr
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer

Summer Studentship Awards

John de Almeida
University of Toronto Life Sciences Award **1999**
$4000 ($CDN)

Andrea Milic
Medical Research Council of Canada, Summer Studentship **1999 and 2000**
$4000 each yr ($CDN)

Jeff Rothenstein
Faculty of Medicine Summer Scholarship **2001**
$4,000 ($CDN)

Kathy Han
University of Toronto Summer Undergraduate Studentship **2001 and 2002**
$4,500 ($CDN)

Susie Chen
University of Miami ACS Summer Studentship **2003**
$2,500 ($US**)**

Anze Urh
University of Miami ACS Summer Studentship **2004**
$2,500 ($US)

Victoria Chan
American Cancer Society **2006**
$2,500

Editorial Responsibilities

Ad hoc Journal Review

- Cell, Science, Nature Medicine, Molecular and Cellular Biology, Oncogene, Carcinogenesis, Cancer Research, Clinical Cancer Research, Cell Growth and Differentiation, American Journal of Pathology, Proceedings of the National Academy of Sciences USA, Genes & Development, Journal of Cell Biology, Journal of Cell Science, International Journal of Cancer, Breast Cancer Research and Treatment

Journal Editorial Boards

- Journal of Clinical Oncology, 2008-present
- Breast Cancer Research, 1999-present

Professional and Honorary Organizations

- Association of American Physicians, Elected Member, 2010
- American Medical Association, 2005
- American Society for Clinical Investigation, Elected Member, 2002-present
- American Federation for Medical Res earch, Member, 1997-2000
- American Association for Cancer Research, Member, 1995-present
- Ontario Medical Association, Member, 1990-present
- Fellow of the Royal College of Physicians and Surgeons, Canada, 1987-present

Honors and Awards

- Association of American Physicians, elected to membership 2010
- University of Miami Sylvester Comprehensive Cancer Center - Miller School of Medicine Jay Weiss Physician Scientist Award, 2009
- University of Miami Sylvester Comprehensive Cancer Center Outstanding Cancer Research Award, 2008
- Doris Duke Distinguished Clinical Scientist Award, 2006-2011
- Avon / AACR Molecular Targeted Therapies to Reverse Antiestrogen Resistance in Breast Cancer, 2006-2007
- Breast Cancer Research Foundation Award, 2006
- American Society for Clinical Investigation Election, 2002
- Senior Clinician-Research Award of the Department of Medicine of Sunnybrook & Women's College Health Sciences Centre, 2002
- Canada Research Chair in Molecular Medicine, 2001-2006
- Burroughs Wellcome Clinician Scientist Award in Translational Research, 1998-2003
- US Army Breast Cancer Research Program Career Development Award, 1998-2002
- Young Clinician-Research Award of the Department of Medicine of Sunnybrook Health Science Centre, 1998
- American Federation for Clinical Research Foundation, Early Career Development Award, 1995-1998

- Senior Postdoctoral Research Fellowship Award, National Cancer Institute of Canada, 1992-1993
- Post-MD Research Fellowship, National Cancer Institute of Canada, 1988-1992
- Class of Medicine, 1924 War Service Scholarship, University of Toronto, 1981-1982
- University Scholar, McGill University, 1978-1979

Other Professional Activities

Presentations

Invited Seminar Speaker

1. **Slingerland JM.** Cytoplasmic p27 promotes Twist1 induction, EMT, and tumor metastasis, Translational Molecular Pathology Distinguished Speaker Seminar Series, MD Anderson Cancer Center, University of Texas, Houston, TX, September 11, 2014.

2. **Slingerland JM.** Epigenetic targeting of the cancer stem cell hierarchy in triple negative breast cancer, Epigenetics and Cancer Colloquium, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, August 15, 2014.

3. **Slingerland JM.** Pre-clinical and early clinical efficacy of Src and ER inhibition in ER-positive breast and ovarian cancers, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, April 15, 2014.

4. **Slingerland JM.** New links between breast cancer and obesity: adipocyte/cancer cell contact upregulates cytokines that drive tumor progression. British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada, October 7, 2013.

5. **Slingerland JM.** SCF^{SKP2}, a dual ER coactivator & ubiquitin ligase induces late target genes to drive G1-to-S progression, Scripps Research Institute, Jupiter, FL, May 9, 2013.

6. **Slingerland JM.** Effects of an adipose tumor microenvironment on breast tumor initiating cell activity. Women's Cancer Program Seminar, Robert Lurie Cancer Center, Northwestern University, Evanston, IL, April 26, 2013.

7. **Slingerland JM.** Effects of an adipose tumor microenvironment on breast tumor initiating cell activity. ITMAT Seminar Series. Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, March 22, 2013.

8. **Slingerland JM**. Evidence for a hierarchy in breast cancer stem cells: Relevance to cancer therapy and metastasis. Oncology Seminar, Stanford University School of Medicine, Stanford, CA, April 12, 2012.

9. **Slingerland JM.** Cytokines and cancer stem cells: Insights on obesity as a risk factor for cancer. UCSF Breast Oncology Program, University of California-San Francisco, CA,

April 11, 2012.

10. **Slingerland JM.** Evidence for a functional and molecular hierarchy within cancer stem cells in ER-negative breast cancer. University of Colorado Cancer Center, University of Colorado Medical Campus, Denver, CO, March 22, 2012.

11. **Slingerland JM.** Effects of an adipocyte mircoenvironment on cancer stem cells and progression. Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, March 6, 2012.

12. **Slingerland JM.** Evidence for a hierarchy within breast cancer stem cell populations: relevance to metastasis and therapy. Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, PA, December 20, 2011.

13. **Slingerland JM.** Personalized breast cancer care: the myth and the promise. Current Concepts in Breast Cancer II – Multidisciplinary Tumor Board Mini-Symposium, Florida International University Herbert Wertheim College of Medicine, North Miami, FL, September 9, 2011.

14. **Slingerland JM.** New mechanisms governing the pro-metastatic action of p27. Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY, June 15, 2011.

15. **Slingerland JM.** Adipocyte-epithelial contact yields cytokines that drive mammary epithelial cell self-renewal and tumorigenesis. Division of Human Biology Seminar Series, Fred Hutchinson Cancer Research Center, Seattle, WA, February 24, 2011.

16. **Slingerland JM.** The Jekyll and Hyde of p27 in cancer progression. Stanford University School of Medicine, Palo Alto, CA, July 22, 2010.

17. **Slingerland JM.** Functional regulation of p27: both loss and gain of function promote cancer progression. Tulane University School of Medicine, New Orleans, LA, April 29, 2010.

18. **Slingerland JM.** Molecular rationale for targeting Src and estrogen signaling in breast cancer. Medicine Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY, April 16, 2010.

19. **Slingerland JM.** New mechanistic insights into ER proteolysis: role of Src and relevance to ER negative breast cancer. Breast Cancer Research Program Lecture, MD Anderson Cancer Center, Houston, TX, March 4, 2010.

20. **Slingerland JM.** The Jekyll and Hyde of p27: tumor suppressor and oncogenic roles in cancer progression. Northwestern University, Chicago, IL, January 29, 2010.

21. **Slingerland JM.** The paradox of p27: mechanisms whereby p27 loss and gain of function may contribute to cancer. Cell Cycle & Cancer Seminar Series, Università degli Studi

"Magna Graecia" di Catanzaro, Italy, September 15, 2009.

22. **Slingerland JM.** Functional regulation of p27: both loss and gain of function promote cancer progression. Johns Hopkins School of Medicine, Baltimore, MD, June 12, 2009.

23. **Slingerland JM.** Functional regulation of p27: both loss and gain of function promote cancer progression. University of Pittsburgh, Pittsburgh, PA, May 21, 2009.

24. **Slingerland JM.** Mechanisms underlying ER-negative breast and ovarian cancer. Breast Cancer Research Program Lecture University of Virginia, Charlottesville, VA, February 6, 2009.

25. **Slingerland JM.** Src as a target in antiestrogen-resistant breast cancer. Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada, May 8, 2008.

26. **Slingerland JM.** The role of Src in human breast cancer progression. Vanderbilt-Ingram Cancer Center, Nashville, TN, April 24, 2008.

27. **Slingerland JM.** Src: A key mediator of p27 proteolysis and target for cancer therapy. Rambam Healthcare Campus, Haifa, Israel, September 3, 2007.

28. **Slingerland JM.** An introduction to Cancer Stem Cells. Stem Cell Conference, Interdisciplinary Stem Cell Institute, Miami, FL, May 1, 2007.

29. **Slingerland JM.** Accelerate proteolysis of p27 in human cancers through Src dependent phosphorylation. UMSCCC Oncology Fellows Lecture, University of Miami Miller School of Medicine, Miami, FL, February 15, 2007.

30. **Slingerland JM.** Mechanisms whereby Src activates estrogen-activated ER proteolysis and ER target gene expression in breast cancer cells. Research Seminar Series. Karmanos Cancer Institute, Detroit, MI, March 14, 2006.

31. **Slingerland JM.** New insights into molecular mechanisms of steroid resistant breast cancer. Women Cancer Research Group Meeting, University of Texas MD Anderson Cancer Center, Houston TX, February 8, 2006.

32. **Slingerland JM.** Src activation: New roles in estrogen receptor target gene expression and proteolysis. Research Seminar – Mt. Sinai School of Medicine, New York, NY, November 11, 2005.

33. **Slingerland JM.** Molecular therapeutic strategies to oppose antiestrogen resistance. Massachusetts General Hospital Breast Conference, Harvard University, Boston, MA, March 1, 2005.

34. **Slingerland JM.** Cell cycle regulators and tamoxifen resistance. Joint Cancer Conference, Orlando, FL, January 30, 2005.

35. **Slingerland JM.** Regulation of G1 progression by the P13K/PKB pathway and its deregulation in cancer. Breakthrough Breast Center Research Center Seminar, Institute for Cancer Research, London, England, January 24, 2005.

36. **Slingerland JM.** G_1 cell cycle regulation by the P13K/Akt pathway. University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA, June 25, 2004.

37. **Slingerland JM.** G_1 cell cycle regulation by the P13K/Akt pathway. Genentech, South San Francisco, CA, June 24, 2004.

38. **Slingerland JM.** MAPK signaling in tamoxifen resistance. University of Toronto Breast Cancer Symposium 2003: Advances in Breast Cancer: From Molecular Pathology and Imaging to Therapeutics, Toronto, Canada, June 20-21, 2003.

39. **Slingerland JM.** How oncogenic activation of MAPK and P13K/PKB impair p27 function. Cancer Biology Seminar, DCS, Copenhagen, Denmark, May 9-11, 2003.

40. **Slingerland JM.** Deregulation of the CDK inhibitor p27 by PKB in human cancers. Apoptosis, Cell Cycle, and Signaling Seminar Series, MD Anderson Cancer Center, Houston, TX, March 10, 2003.

41. **Slingerland JM.** p27 deregulation in breast cancer. University of Miami, Department of Medicine, Miami, FL, February 4, 2003.

42. **Slingerland JM.** Regulation of the estrogen receptor by proteolysis: relevance to ER negative breast cancer. Inaugural Landon-AACR Research Awards Symposium, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, January 17, 2003.

43. **Slingerland JM.** Mechanisms of resistance to antiestrogen therapy in breast cancer: new molecular insights. The ECOG Annual Meeting, Miami, FL, Nov 18, 2002.

44. **Slingerland JM.** PKB phosphorylates p27 and leads to its cytoplasmic mislocalization – relevance to human breast cancer. Research Seminar, Palo Alto Medical Foundation, Stanford University, CA, April 4, 2002.

45. **Slingerland JM.** PKB phosphorylates p27 and leads to its cytoplasmic mislocalization – relevance to human breast cancer. Research Seminar, University of California at San Francisco, CA, April 2, 2002.

46. **Slingerland JM.** Cytoplasmic mislocalization of the cdk inhibitor p27: links to oncogenic PKB activity and prognostic import in human breast cancer. Research Seminar, Baylor College of Medicine, Houston, TX, February 4, 2002.

47. **Slingerland JM.** Degradation or mislocalization of the cdk inhibitor p27: Prognostic import in human breast cancer. Oncology Grand Rounds, Rochester Cancer Center, Rochester, NY, January 27, 2002.

48. **Slingerland JM.** Deregulation of the cell cycle inhibitor p27 in human breast cancer. Oncology Rounds, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, November 27, 2001.

49. **Slingerland JM.** $p27^{Kip1}$, a novel prognostic factor and predictor of tamoxifen responsiveness in breast cancer. Cancer Education Seminars (part of Medical Oncology training series), Stanford University Medical Center, Palo Alto, CA, August 14, 2001.

50. **Slingerland JM.** p27: A new prognostic factor – the bench to bedside story. Medical Grand Rounds, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, January 23, 2001.

51. **Slingerland JM.** Nuclear export of p27 is regulated by phosphorylation and by ranGTP/CRM1 binding. Trescowthick Research Laboratories, Peter MacCallum Cancer Institute, Melbourne, Australia, November 24, 2000.

52. **Slingerland JM.** Nuclear export of p27 is regulated by phosphorylation and by ranGTP/CRM1 binding. Garvan Institute of Medical Research, Sydney, Australia, November 20, 2000.

53. **Slingerland JM.** Nuclear export of p27 is regulated by phosphorylation and by ranGTP/CRM1 binding. Friedrick Miescher Institut, Basel, Switzerland, October 31, 2000.

54. **Slingerland JM.** How to move a molecular from the bench to the bedside: The p27 story and breast cancer. Oncology Grand Rounds, Sunnybrook & Women's College Health Sciences Center, Toronto, May 31, 2000.

55. **Slingerland JM.** An update on p27 as a prognostic factor in human cancers. Progress in Pathology Rounds, Sunnybrook & Women's College Health Sciences Centre, Toronto, May 30, 2000.

56. **Slingerland JM.** Molecular epidemiology applied to Oncology. Lecture series for the Oncology Fellows, Toronto-Sunnybrook Regional Cancer Centre, Toronto, April 26, 2000.

57. **Slingerland JM.** Interaction of TGF-β signaling and mitogenic pathways in the regulation of the cell cycle inhibitor, p27. The 3rd Annual Cell Signaling Technology/New England Biolabs Signal Transduction Symposium, Toronto, Ontario, April 14, 2000.

58. **Slingerland JM.** The cell cycle inhibitor p27 is a novel prognostic factor and an essential mediator of the effects of tamoxifen in breast cancer. University of Calgary Cancer Biology Research Seminar, Calgary, Alberta, March 23, 2000.

59. **Slingerland JM.** The cell cycle inhibitor p27 is a novel prognostic factor and an essential mediator of the effects of tamoxifen in breast cancer. Oncology Grand Rounds, London Regional Cancer Centre, London, Ontario, March 7, 2000.

60. **Slingerland JM.** How to move a molecule from the bench to the bedside: The p27 story and breast cancer. Breast Cancer Research Meeting, Vaughan Estate, Estates of Sunnybrook, Toronto, February 29, 2000.

61. **Slingerland JM.** p27 in and out of the nucleus: Mechanisms regulating nuclear export. Department of Pathology Research Seminar, New York University Medical Center, New York, NY, February 8, 2000.

62. **Slingerland JM.** The cell cycle inhibitor p27 is a novel prognostic factor and an essential mediator of the effects of tamoxifen in breast cancer. Research Seminar, Ontario Cancer Institute, Toronto, ON, January 11, 2000.

63. **Slingerland JM.** Changes in p27 phosphorylation, localization, and loss of cdk inhibitory function in TGF-β resistant breast epithelial cells. Cancer Research Laboratories, Queen's University, Kingston, ON, December 7, 1999.

64. **Slingerland JM.** Changes in p27 phosphorylation, localization, and loss of cdk inhibitory function in TGF-β resistant breast epithelial cells. Research Institute Seminar, The Hospital for Sick Children, Toronto, ON, December 3, 1999.

65. **Slingerland JM.** Changes in p27 phosphorylation, localization, and loss of cdk inhibitory function in TGF-β resistant breast epithelial cells. Loeb Institute Seminar, Ottawa, ON, November 29, 1999.

66. **Slingerland JM.** Altered p27 phosphorylation, localization, and function in TGF-β resistant human mammary epithelial cells. Department of Biochemistry and Biophysics Basic Science Lecture, University of Rochester Medical Center, Rochester, NY, October 27, 1999.

67. **Slingerland JM.** p27: An essential effector of growth arrest by tamoxifen and a novel prognostic factor in breast cancer. City Wide Hematology-Oncology Conference, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, October 26, 1999.

68. **Slingerland JM.** Altered post-transcriptional regulation of the cdk inhibitor p27 in TGF-β resistant breast cells. Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland, October 22, 1998.

69. **Slingerland JM.** Loss of the cell cycle inhibitor $p27^{Kip1}$ as a prognostic factor in human breast and prostate cancer. Vancouver Cancer Centre, Vancouver, BC, April 21, 1998.

70. **Slingerland JM**, Cariou S, Catzavelos C. Loss of Cdc25A contributes to G1 arrest at senescence in human mammary epithelial cells. Department of Biochemistry Seminar, University of British Columbia, Vancouver, BC, April 20, 1998.

71. **Slingerland JM.** Altered regulation of $p15^{INK4B}$ and $p27^{Kip1}$ in TGF-β resistant cells: Evidence for a novel inhibitor of p27. The Vanderbilt Cancer Center, Nashville, TN, December 2, 1997.

72. **Slingerland JM.** Advances in Prostate Cancer treatment, research trends, and options. Prostate Health Awareness Forum, Glaxo Wellcome, Toronto, ON, November 18, 1997.

73. **Slingerland JM.** Loss of the cell cycle inhibitor p27: A new prognostic factor in breast and prostate cancer. Medical Grand Rounds, Sunnybrook Health Science Centre, Toronto, ON, November 11, 1997.

74. **Slingerland JM.** Altered regulation of the cdk inhibitors p15 and p27 in TGF-β resistant human mammary epithelial cells. Eli-Lily Research Group, Indianapolis, IN, June 23, 1997.

75. **Slingerland JM.** Altered regulation of the cdk inhibitors p15 and p27 in TGF-β resistant human mammary epithelial cells. Harvard University MGH Cancer Centre, Massachusetts General Hospital, Charlestown, MA, May 14, 1997.

76. **Slingerland JM.** p27 as a prognostic factor in human adenocarcinomas. Nursing In-Service Seminar, Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, April 4, 1997.

77. **Slingerland JM.** Loss of the cell cycle inhibitor p27: A new prognostic factor for breast cancer. Internal Medicine Grand Rounds, Women's College Hospital, Toronto, ON, March 26, 1997.

78. **Slingerland JM.** TGF-β stabilizes $p15^{INK4B}$, increases $p15^{INK4B}$/cdk4 complexes, and inhibits cyclin D1/cdk4 association in human mammary epithelial cells. Terry Fox Immunology & Cancer Research Seminar, Hospital for Sick Children, Toronto, January 15, 1997.

79. **Slingerland JM.** p27 as a prognostic factor in human adenocarcinomas. Women's College Hospital Breast Research Rounds, Women's College Hospital, Toronto, ON, November 29, 1996.

80. **Slingerland JM.** p27 as a prognostic factor in human adenocarcinomas. Medical Oncology Grand Rounds, Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, November 27, 1996.

81. **Slingerland JM.** p27 in breast cancer. Breast Site Group Conference, Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, October 31, 1996.

82. **Slingerland JM.** Cell cycle responses to negative regulatory signals. Reproductive Biology Group Seminar, Loeb Medical Research Institute, Ottawa Civic Hospital, Ottawa, October 23, 1996.

83. **Slingerland JM.** Molecular Biology of Breast Carcinoma. Pharmaceutical Representative Preceptorship, Toronto-Sunnybrook Regional Cancer Centre, Toronto, September 5, 1996.

84. **Slingerland JM.** Resistance of breast cancer cells to growth inhibition by TGF-β. Breast Site Group Conference, T-SRCC, Toronto, January 25, 1996.

85. **Slingerland JM.** The cell cycle response to UVB induced DNA damage. Combined PMH/T-SRCC Medical Oncology Rounds, November 2, 1995.

86. **Slingerland JM.** Mechanisms of resistance of TGF-β. Department Clinical Biochemistry - Faculty Research Focus Hour, University of Toronto, May 1, 1995.

87. **Slingerland JM.** A novel inhibitor of cyclin/cdk activity in TGF-β arrested epithelial cells. Scientific Seminar Medical Biophysics, Ontario Cancer Institute, Toronto, November 24, 1994.

88. **Slingerland JM.** Mechanisms of resistance of TGF-β. Oncology Grand Rounds, Princess Margaret Hospital, Toronto, November 23, 1994.

89. **Slingerland JM.** Cell cycle regulation in cancer. Combined PMH/T-SRCC Medical Oncology Rounds, Toronto, June 2, 1994.

90. **Slingerland JM.** Cell cycle regulators and cancer. Medical Grand Rounds, SHSC, May 31, 1994.

91. **Slingerland JM.** The cell cycle in cancer. Oncology Grand Rounds, T-SRCC, May 25, 1994.

92. **Slingerland JM.** A novel inhibitor of cyclin/cdk activity in β arrested epithelial cells. Hematology/Oncology Rounds, Clinical Science Division, February 25, 1994.

93. **Slingerland JM.** Wheels within wheels: The cell cycle and cancer. Medical Grand Rounds, SHSC, December 14, 1993.

Plenary Speaker at International Meetings

1. **Slingerland JM.** New links between breast cancer and obesity: adipocyte/cancer cell contact upregulates cytokines that drive tumor progression. Breast Cancer Think Tank 24 Curacao, January 12-18, 2014

2. **Slingerland JM** Transcription-coupled ERα Proteolysis: Implications for Hormone-Dependent Cancers: Hormone Action in Cancers Beyond Breast & Prostate. Gordon Research Conference, Smithfield, RI, USA, July 28-August 2, 2013.

3. **Slingerland JM**. Pre-clinical and early clinical efficacy of Src inhibition combined with antiestrogens in ER-positive Breast & Ovarian Cancers, ENDO Society meeting, San Francisco, CA, USA, June 17-18, 2013.

4. **Slingerland JM**. Effects of an adipocyte microenvironment in cancer stem cells and cancer progression. Expedition Inspiration: The Role of Inflammation & Immunity in Breast Cancer Etiology & Treatment, Sun Valley, ID, USA, February 12-16, 2013.

5. **Slingerland JM.** The SCF^{Skp2} E3 ligase promotes cell cycle progression via dual roles as co-activator and E3 ligase for estrogen receptor α. Integration of Genomic and Non-Genomic Steroid Receptor Actions, Snowmass, CO, USA, July 29 – August 3, 2012.

6. **Slingerland JM.** $CD44^{+}CD24^{low+}$ progenitors in ER negative breast cancer generate CD44+CD24neg cells, and show increased Notch1-mediated Sox2 activation, increased self-renewal and greater metastatic potential. 28th International Association for Breast Cancer Research (IABCR)/Breakthrough Breast Cancer Conference, Stromal-Epithelial Interactions in Breast Cancer Development and Progression, Manchester, UK, April 15-18, 2012.

7. **Slingerland JM.** Evidence for a hierarchy within breast cancer stem cell populations: relevance to metastasis and therapy. Think Tank 22, Mayan Riviera, Mexico, January 15-21, 2012.

8. **Slingerland JM.** Further adventures with cytokines and stem cells. Think Tank 21, Montego Bay, Jamaica, January 16-22, 2011.

9. **Slingerland JM.** The role of ERαY537 phosphorylation in coupling ligand activated ER transcriptional activity with receptor proteolysis. (conference organizer) FASEB Summer Research Conference: The Physiology of Integrated Nuclear and Extranuclear Steroid Signaling, Snowmass Village, CO, August 8-13, 2010.

10. **Slingerland JM.** Src drives ligand-activated ER proteolysis and transcriptional activity. Pfizer Estrogens, SERMs and TSECs Meeting, Philadelphia, PA, April 20-22, 2010.

11. **Slingerland JM.** The Jekyll and Hyde of p27: how a tumor suppressor is subverted to promote cell migration and metastasis. Nature Biotech/Miami Winter Symposium 2010, Miami, FL, February 21-24, 2010.

12. **Slingerland JM.** Mechanism whereby adipocytes influence mammary epithelial cell numbers, motility, and stem cell function. Think Tank 20, Barbados, West Indies, January 18, 2010.

13. **Slingerland JM.** Kinase signaling and ER status in breast cancer. ENDO 09 Annual Meeting of the Endocrine Society, Washington, DC, June 10-13, 2009.

14. **Slingerland JM.** Functional regulation of the Cdk inhibitor p27: Both loss and gain of function promote cancer progression. AACR 100th Annual Meeting 2009, Denver, Colorado, April 18-22, 2009.

15. **Slingerland JM**. Targeting mTOR to inhibit cancer cell growth and cell cycle. Session chair, AACR 100th Annual Meeting 2009, Denver, Colorado, April 18-22, 2009.

16. **Slingerland JM.** Cell cycle regulation by TORC1 and 2, SKG, and Akt: an AGC kinase affair. The LAM Foundation 2009 International Research Conference, Cincinnati, Ohio, April 17, 2009.

17. **Slingerland JM.** From PI3K to p27: many roads lead to Rome. Breast Cancer Symposium Think Tank 19, San Jose, Costa Rica, January 11-17, 2009.

18. **Slingerland JM.** Rationale for targeting Src in breast cancer therapy. The 8th Annual Princess Margaret Hospital Conference, Toronto, Ontario, October 16-18, 2008.

19. **Slingerland JM.** Src and ligand-activated ER alpha proteolysis: relevance to breast cancer and beyond. FASEB Conference: Non-genomic Actions of Steroid Hormones Carefree, AZ, July 27 – August 1, 2008.

20. **Slingerland JM.** Molecular rationale and preclinical data to support combined Src and aromatase inhibitor therapy for ER-positive breast cancer. Session chair, AACR Translational Cancer Medicine 2008, Monterey, CA, July 20-23, 2008.

21. **Slingerland JM.** Src promotes estrogen-dependent era proteolysis in human breast cancer. Keystone Symposium – Nuclear Receptors: Steroid Sisters, Whistler, British Columbia, Canada, March 31, 2008.

22. **Slingerland JM.** Molecular targeted therapy for treatment of endocrine resistant breast cancers. The 13th Annual Multidisciplinary Symposium on Breast Disease, Jacksonville, FL, February 15, 2008.

23. **Slingerland JM.** Biologic insights into ER-negative breast cancer. Lynn Sage Breast Cancer Symposium – Chicago, Illinois, September 27-29, 2007.

24. **Slingerland JM.** The role of Src in p27 function and antiestrogen resistance in human breast cancer. The 2nd Symposium on Fertility and Gender Specific Cancer, Women's Health Research Center at the Weizmann Institute of Science, Rehovot, Israel, September 4-5, 2007.

25. **Slingerland JM.** cSrc activates both estrogen:ER target gene expression and ER proteolysis: relevance to ER-negative breast cancer. Expedition Inspiration Sun Valley, Idaho, February 28 – March 4, 2007.

26. **Slingerland JM.** Molecular strategies for treating hormone resistant breast cancer. Hormonal Control of the Cell Cycle, Foundation IPSEN, Paris, France, December 1-6, 2006.

27. **Slingerland JM.** Cell cycle targeting agents. American Society of Clinical Oncology

(ASCO) Aspen, CO, August 11-13, 2006.

28. **Chu I, Slingerland J.** p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk 2. Cold Spring Harbor Meeting on the Cell Cycle, Cold Spring Harbor, NY, May 17-21, 2006 (presented by my graduate student).

29. **Slingerland JM.** Alteration of p27 in breast cancer. 19th Annual MD Anderson Radiation Workshop at Round Top Texas 2005: Advances in Cell Cycle Regulation and Breast Cancer, Round Top, TX, April 21-24, 2005.

30. **Slingerland JM.** Cell cycle regulators and tamoxifen resistance. Joint Cancer Conference, Orlando, FL, January 30, 2005.

31. **Slingerland JM.** Regulation of G1 progression by the P13K/PKB pathway and its deregulation in cancer. Cell and Molecular Biology of Cancer, ISREC Conference, Lausanne, Switzerland, January 19-22, 2005.

32. **Slingerland JM.** Reduced p27 levels in Human Breast Cancer: Prognostic and Therapeutic Implications. AACR Special Conference on Cell Cycle and Cancer: Pathways and Therapies, Ft. Lauderdale, FL, December 1-5, 2004.

33. **Slingerland JM.** Cell Cycle Regulators and Tamoxifen Resistance. 2nd Inter-American Breast Cancer Conference, Cancun, Mexico, July 21-24, 2004.

34. **Slingerland JM.** Akt/PKC-dependent phosphorylation of p27 activates the cyclin D1/Cdk4 assembly function of p27 and G1 cell progression. Korean Society for Medical Biochemistry and Molecular Biology, Seoul, Korea, October 29-30, 2003.

35. **Slingerland JM.** Src and Her2 cooperate to constitutively activate ligand-dependent ER proteolysis in ER-negative breast cancer cells. Canadian Breast Cancer Research Alliance, Third Scientific Conference, Ottawa, Canada, October 26, 2003.

36. **Slingerland JM.** Molecular targeted therapies for breast cancer. 94th Annual Meeting of the AACR, Washington, DC, July 11, 2003.

37. **Slingerland JM.** Cell cycle regulation and cancer – how oncogenic activation of MAPK and P13K/PKB impair p27 function. Fifth Meeting of Molecular Oncology, Positano, Italy, May 12–15, 2003.

38. **Slingerland, JM.** MAPK signaling in tamoxifen resistance. University of Toronto Breast Cancer Symposium: Advances in Breast Cancer: From Molecular Pathology and Imaging to Therapeutics, Toronto, ON, Canada, June 20-21, 2003.

39. **Slingerland, JM.** Mechanisms of resistance to hormonal therapy in breast cancer. Joint Cancer Conference of the Florida Universities, Orlando, FL, February 20-22, 2003.

40. **Slingerland, JM.** Loss of growth inhibitory function of p27 by oncogenic activation of MAPK and P13K/PKB signaling. Miami Nature Biotechnology Winter Symposia, Miami, FL, February 1-5, 2003.

41. **Liang J, Slingerland JM.** Akt/PKB-dependent phosphorylation of p27 activates the cyclin D1/Cdk4 assembly function of p27 and G1 cell cycle progression. The Cell Cycle, Cold Spring Harbor, May 17, 2002 (presented by my graduate student).

42. **Slingerland JM.** The MAPK pathway: new molecular targets for the therapy of hormone resistant breast cancer. 4rth International Conference on Sex and Gene Expression, San José, April 5-7, 2002.

43. **Slingerland JM.** Ligand dependant ER degradation: a non-genomic effect of ligand estrogen/ER binding. Genomic vs. Non-Genomic Steroid Actions: Encountered or Unified Views, Juan March Institute, Madrid, Spain, December 17, 2001.

44. **Catzavelos C**, Hanna W, Andrulis I, Bull S, **Slingerland JM.** p27, a new prognostic factor for breast cancer. Reasons for Hope 2001, Quebec City, Quebec, May 4, 2001 (presented by my collaborator, Dr. Catzavelos).

45. **Slingerland JM.** Activation of PKB opposes TGF-β-mediated G1 arrest through effects on p27 phosphorylation. Reasons for Hope 2001, Quebec City, Quebec, May 4, 2001.

46. **Slingerland JM.** p27, a novel molecular marker of prognosis. Fourth Leura International Breast Cancer Conference, Leura, Australia, November 17, 2000.

47. **Slingerland JM.** The MAPK pathway: New molecular targets for the therapy of hormone resistant breast cancer. Hormones and Cancer (HC2000) meeting, Port Douglas, Australia, November 4, 2000.

48. **Slingerland JM.** New insights on p27 degradation and the prognostic role of p27 in human cancer. Impact of Cancer Biotechnology on Predictive Oncology & Therapy, 5th International Symposium, Geneva, Switzerland, October 28, 2000.

49. **Connor M,** Cariou S, Kotchetkiv R, Mechior F, **Slingerland J.** Mechanisms regulating p27 nuclear export. Cold Spring Harbor Meeting on the Cell Cycle, Cold Spring Harbor, NY, May 17-20, 2000 (presented by my post-doctoral fellow, M. Connor).

50. **Slingerland JM.** p27: A novel prognostic factor and an essential mediator of the therapeutic effects of tamoxifen in breast cancer. Cancer Care Ontario 17th Biennial Research Conference Hormone Dependent Tumours: Biology, Prevention and Therapy, Geneva Park, Ontario, November 8-10, 1999.

51. **Slingerland JM.** Regulation of the cell cycle inhibitor p27 by estrogens and antiestrogens. World Conference on Breast Cancer, Ottawa, Ontario, July 26-31, 1999.

52. **Slingerland JM.** Activation of P13K/PKB leads to loss of TGF-β responsiveness, and changes in p27 phosphorylation. The Cell Cycle Meeting, The Salk Institute for Biological Studies, San Diego, CA, June 18-22, 1999.

53. Yacoub N, Geldenhuys L, Kapusta L, Moason L, **Slingerland JM**, **Catzavelos C.** p27 levels in multistep breast cancer progression. Canadian Breast Cancer Research – Reasons for Hope National Scientific Conference, Toronto, June 17-19, 1999 (presented by my collaborator Dr. C. Catzavelos).

54. **Donovan J**, Cariou S, Bhattacharya N, **Slingerland JM.** Regulation of the cell cycle inhibitor p27 by estrogens and antiestrogens. Reasons For Hope Conference, Canadian Breast Cancer Research Initiative, Toronto, Canada, June 17-19, 1999 (presented by my graduate student, J. Donovan).

55. **Cariou S,** Bhattacharya N, **Slingerland JM.** Post-translational regulation of the cell cycle inhibitor $p27^{Kip1}$ by estrogens. Reasons For Hope Conference, Canadian Breast Cancer Research Initiative, Toronto, Canada, June 17-19, 1999 (presented by my post-doc, S. Cariou).

56. **Slingerland JM.** Post-translational changes in $p27^{Kip1}$ in TGF-β resistant mammary epithelial cells. Reasons For Hope Conference, Canadian Breast Cancer Research Initiative, Toronto, Canada, June 17-19, 1999.

57. **Slingerland JM.** Loss of the cdk inhibitor p27: A novel prognostic factor in common human cancers. International Symposium on Predictive Oncology & Therapy, Nice, France, Oct. 24-27, 1998.

58. **Tsihlias J**, Klotz LH, **Slingerland JM.** Growth arrest of LNCaP human prostate cancer cells by high dose dihydrotestosterone: Effect on cell proliferation and changes in the cell cycle regulatory proteins. American Urological Association 1998 Annual Meeting, San Diego, CA, May 29-June 5, 1998.

59. **Slingerland JM.** Prognostic implications of expression of cell cycle inhibitor protein $p27^{Kip1}$. Controversies in the Etiology Detection and Treatment of Breast Cancer 1998, The Old Mill, Toronto, May 28-29, 1998.

60. **Sandhu C, Slingerland JM.** Involvement of Cdc25A in human mammary epithelial cell senescence. Cold Spring Harbor Meeting on the Cell Cycle, Cold Spring Harbor, NY, May 20-24, 1998 (presented by my graduate student, C. Sandhu).

61. **Slingerland JM.** Mechanisms of cdk inhibition senescent human mammary epithelial cells. 11^{th} European Cell Cycle Conference, Gardone Riviera, Italy, April 22-26, 1997.

62. **Slingerland JM.** Evidence for altered regulation of the cell cycle inhibitor $p27^{Kip1}$ in breast cancer and in TGF-β resistant breast lines. American Association for Cancer Research, Basic and Clinical Aspects of Breast Cancer, Keystone, CO, March 7-12, 1997.

63. **Slingerland JM.** Altered regulation of the cdk inhibitors contributes to TGF-β resistance and cancer progression. TGF-β Signaling in Development and Cell Cycle Control Symposium, Madrid, Spain, February 10-12, 1997.

64. **Slingerland JM.** How breast cancers escape from negative growth controls. Controversies in the Etiology, Detection and Treatment of Breast Cancer, Toronto, May 3, 1996.

65. **Slingerland JM,** Garbe J, Pan C-H, Hosoda J, Daksis J, Stampfer M. Mechanisms of resistance to transforming growth factor-beta (TGF-β) induced cell cycle arrest in human mammary epithelial cells. The 86th Annual Meeting of the American Association for Cancer Research, Toronto, Canada, March 1995.

Poster Presentations at International Meetings

1. Dekuang Zhao, Chendong Pan, Jun Sun, Katherine Drews-Elger, Manuel Picon-Ruiz, Guy Howard, and **Slingerland JM**. Adipocyte-cancer cell contact drives cancer initiating cells via VEGF-dependent upregulation of Myc and Sox2. Cell Symposia – Immunometabolism: from Mechanisms to Therapy. Toronto, Canada, June 2013.

2. Zhou W, Sun J, Srinivasan S, Nawaz Z, **Slingerland JM**. SCF/Skp2 E3 ligase promotes G1/S transition by ubiqutinating and activating estrogen receptor α. FASEB Summer Research Conference "The Physiology of Intergrated Nuclear and Extranuclear Steroid Signalling", July 29-August 3, 2012, Snowmass Village, CO.

3. Sun J, Zhou **W,** Kaliappan K, Nawaz Z, **Slingerland JM**. ER Y537 phosphorylation triggers E6-AP recruitment as ER coactivator and ubiquitin ligase. FASB meeting 2012, Colorado Springs, CO, June 2012.

4. Zhou W, Sun J, **Slingerland JM.** The SCF F box protein, Skp2, is a key component of an E3 ubiquitin ligase that governs estrogen receptor α stability. AACR 103rd Annual Meeting 2012, Chicago, IL, March 2012.

5. Azzam DJ, Drews-Elger K, Zhao D, Ranganathan P, Capobianco A, Minn AJ, Creighton C, Picon-Ruiz M, Sun J, Pan C, Wander SA, El-Ashry D, **Slingerland JM.** $CD44^{+}CD24^{low+}$ progenitors in ER negative breast cancer have higher Notch1 activation, self-renewal, and chemo resistance and generate $CD44^{+}CD24^{neg}$ cells and tumors that metastasize. AACR 103rd Annual Meeting 2012, Chicago, IL, March 2012.

6. **Besser AH**, Wander SA, Zhao D, Hong F, Wei JQ, Wang B, Ince T, Milikowski C, Nadji M, Briegel K, Bishopric N, **Slingerland JM.** Targeted PI3K/mTOR inhibition impairs tumor cell motility and bone metastatic outgrowth via modulation of p27. AACR 103rd Annual Meeting 2012, Chicago, IL, March 2012.

7. **Boelens MC**, Wu TJ, Yoon T, Azzam D, **Slingerland JM**, Minn AJ. Stroma-mediated DNA damage resistance of human breast cancer. AACR 103rd Annual Meeting 2012, Chicago, IL, March 2012.

8. Perez A, Neskey DM, Wen J, Goodwin WJ, **Slingerland JM**, Pereira L, Weigand S, Franzmann EJ. Targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083. AACR 103rd Annual Meeting 2012, Chicago, IL, March 2012.

9. Wander SA, Zhao D, Hong F, Pan C, Chen Y, Jorda M, **Slingerland JM.** The atypical tumor suppressor p27 regulates cellular proliferation, invasion, and metastasis via subcellular localization in distinct microenvironments. AACR 102nd Annual Meeting 2011, Orlando, FL, April 2011.

10. Azzam D, Drews-Elgers K, Zhao D, Chendong P, Wander SA, El-Ashry D, **Slingerland JM.** Self-renewal, tumorigenicity and metastatic potential of $CD44^+$ cells in ER-negative lines and dissociated primary human breast cancers is increased in $CD24^+$ subsets. AACR 102nd Annual Meeting 2011, Orlando, FL, April 2011.

11. Azzam D, Drews-Elgers K, Zhao D, Chendong P, Wander SA, El-Ashry D, **Slingerland JM.** Self-renewal, tumorigenicity and metastatic potential of $CD44^+$ cells in ER-negative lines and dissociated primary human breast cancers is increased in $CD24^+$ subsets. Keystone Symposium: Stem Cells, Cancer and Metastasis (C4), Keystone, CO, March 2011.

12. Wander SA, Zhao D, Hong F, Wei J, Bishopric N, **Slingerland JM.** PI3K/mTOR signaling promotes p27-dependent tumor cell motility and bone metastasis. AACR: Targeting PI3K/mTOR Signaling in Cancer, San Francisco, CA, February 2011.

13. **Xie Y**, Sun J, Zhou W, **Slingerland JM.** Src signalling promotes ligand-activated ER proteolysis. FASEB Summer Research Conference: The Physiology of Integrated Nuclear and Extranuclear Steroid Signaling, Snowmass Village, CO, August 2010.

14. Zhou W, Sun J, Kaliappan K, Nawaz Z, **Slingerland JM.** The roles of E6AP and SCF (Skp1·CUL1·F-box) in Src-stimulated, estrogen-activated ER proteolysis and transactivation. FASEB Summer Research Conference: FASEB Summer Research Conference The Biology of Integrated Nuclear and Extranuclear Steroid Signaling, August 8-13, 2010, Snowmass Village, CO.

15. Ochoa R, Mendiola M, Sudhindra A, Rainwater C, Gomez C, Hurley J, **Slingerland JM**, Pearson M, Lucci J, Lambrou N, Mendez L, Ruiz B, Glück S, Kneuper-Hall R, Silva O. Clinical patterns of breast cancer metastatic to gynaecologic organs and peritoneum. 5th Inter-American Breast Cancer Conference, Cancun, Mexico, June 2010.

16. Sudhindra A, Ochoa R, Mendiola M, Diaz A, Takita C, Hurley J, Glück S, Welsh C, **Slingerland JM**, Richman S, Gomez-Fernandez C, Timothee P, Pimenta J, Silva O**.** Body Mass Index (BMI) and survival: A retrospective review of women with triple negative

breast cancer. 5th Inter-American Breast Cancer Conference, Cancun, Mexico, June 2010.

17. Zhao D, Wander S, Larrea M, **Slingerland JM**. Overexpression of P27 T198 phosphomimetic mutant promotes breast cancer motility independent of cell cycle function. Cold Spring Harbor Meeting: The Cell Cycle, NY, May 2010.

18. Hong F, Wander S, Larrea M, Zhao D, **Slingerland JM**. PI3K activates p27-dependent tumor cell migration and metastasis—Mechanisms beyond RhoA. Cold Spring Harbor Meeting: The Cell Cycle, NY, May 2010.

19. Azzam D, Zhao D, Pan C, Wander SA, **Slingerland JM.** The $CD44^{HIGH}/CD24^{NEG}$ and $CD44^{HIGH}/CD24^{LOW}$ breast cancer cell subpopulations in the MDA-MB-231 line have distinct biological properties. Nature Biotech/Miami Winter Symposium 2010, Miami, FL, February 2010.

20. Pan C, Ince T, Howard G, Schiller P, **Slingerland JM.** Co-culture with adipocytes affects mammary epithelial cell migration and self-renewal via autocrine and paracrine cytokines. Miami Winter Symposium 2010, Nature Biotech/Miami, FL, February 2010.

21. Wander SA, Hong F, Zhao D, Larrea M, Jorda M, **Slingerland JM.** The PI3K pathway promotes p27-dependent tumor cell migration and metastasis. Nature Biotech/Miami Winter Symposium 2010, Miami, FL, February 2010.

22. Xie Y, Sun J, Zhou, **Slingerland JM.** Src signaling promotes ligand-activated ER proteolysis. Nature Biotech/Miami Winter Symposium 2010, Miami, FL, February 2010.

23. Zhao D, Wander SA, **Slingerland JM.** Exploring the role of p27 T157/T198 phosphorylation in breast cancer cell motility. Nature Biotech/Miami Winter Symposium 2010, Miami, FL, February 2010.

24. Hong F, Larrea M, Doughty C, Kwiatkowski DJ, Squillace R, **Slingerland JM.** mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Cold Spring Harbor Laboratory: The Cell Cycle, Cold Spring Harbor, NY, May 14-21, 2008.

25. da Silva, T, Liang J, Farooq A, **Slingerland JM.** A novel phosphorylation site on Cdk2 regulates cyclin binding and G1 progression. Cold Spring Harbor Laboratory: The Cell Cycle, Cold Spring Harbor, NY, May 14-21, 2008.

26. **Slingerland JM,** Liang J, Han K. Phosphorylation of CDK2 at T39 by PKB (AKT) facilitates cyclin-CDK2 association and CAK activation. The Cell Cycle, Cold Spring Harbor Symposium, NY, May 19-23, 2004.

27. Larrea M, **Slingerland JM**. The involvement of $p90^{RSK}$ in the regulation of the Cell Cycle Inhibitor $p27^{Kip}$. The Cell Cycle, Cold Spring Harbor Symposium, NY, May 19-23, 2004.

28. Chu I, Sun J, Arnaout A, **Slingerland JM**. cSrc and Her2 cooperate with estrogen to activate ligand-dependent ERα proteolysis: Implications for therapy of ER negative breast

cancer. Keystone Symposia: Nuclear Receptors: Orphan Brothers and Nuclear Receptors: Steroid Sisters. Keystone, CO, February 28 – March 4, 2004.

29. Chu I, Chang C, Arnaout A, Kahn H, Nawaz Z, **Slingerland JM.** A link between the ER negative status of human breast cancers and accelerated ER proteolysis via cross talk with Her2 and cSrc. 25th San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2002.

30. Chu I, Chang A, **Slingerland JM.** Cross talk with signaling pathways as a mechanism regulating estrogen receptor proteolysis. Endocrine Society 84th Annual Meeting, San Francisco, CA, June 19-24, 2002.

31. Yang L, Radeva G, Dedhar S, **Slingerland JM.** The integrin-linked kinase (ILK) opposes G1 arrest by inhibitory cytokines. The Cell Cycle, Cold Spring Harbor, NY, May 2002.

32. Chu I, **Slingerland JM.** Why do ER negative breast cancers fail to express the ER: mechanisms of ER proteolysis? Reasons for Hope 2001, Quebec City, Quebec, May 4, 2001.

33. Connor M, Cariou S, Kotchetkov R, Beniston R, Hengst L, Melchior F, **Slingerland JM.** Nuclear export of p27 is regulated by CRM1-RanGTP-binding and by phosphorylation. Cell Cycle 2001, Keystone Symposia, Taos, New Mexico, January 9-14, 2001 (presented by my post-doc).

34. Akduman B, Kapusta L, Klotz L, DeBoer G, **Slingerland JM.** Prognostic value of p27Kip1 and SKP2 in prostate adenocarcinoma. European Society of Urological Research Conference, October 2-5, 2000.

35. Cariou S, Donovan J, Flanagan M, Milic A, Bhattacharya N, **Slingerland JM.** The cell cycle inhibitors, p21 and p27, are essential for the therapeutic effects of antiestrogens in human breast cancer cells. Era of Hope DOD Breast Cancer Research Program Meeting, Atlanta, GA, June 8-11, 2000.

36. Subramaniam V, To C, Ciarallo S, Lee J, Stampfer M, **Slingerland JM.** Altered p27 phosphorylation, localization, and function are associated with resistance to TGF-β-mediated G1 arrest. Cold Spring Harbor Meeting on the Cell Cycle, Cold Spring Harbor, NY, May 17-20, 2000 (presented by my research associate, V. Subramaniam).

37. Liang J, Lee J, Ciarrallo S, **Slingerland JM.** Activation of PKB opposes TGF-β-mediated G1 arrest. Cold Spring Harbor Meeting on the Cell Cycle, Cold Spring Harbor, NY, May 17-20, 2000 (presented by my graduate student, J. Liang).

38. Donovan J, Cariou S, Milic A, Bhattacharya N, Flanagan M, **Slingerland JM.** $p27^{Kip1}$: A key effector of estradiol:ER signaling. Signaling 2000, Keystone Symposia, Keystone, CO, January 22-28, 2000.

39. Donovan J, Cariou S, Bhattacharya N, **Slingerland JM.** Regulation of the cell cycle inhibitor p27 by estrogens and anti-estrogens. Salk Institute Cell Cycle Meeting, San Diego, CA, June 18-22, 1999.

40. Lee J, **Slingerland JM.** Role of p13K signal transduction pathway in TGF-β resistance and immortalization of cultured human mammary epithelial cells. Canadian Breast Cancer Research – Reasons for Hope National Scientific Conference, Toronto, June 17-19, 1999.

41. Sandhu C, Bhattacharya N, Peehl D, Stampfer S, **Slingerland JM.** Cell cycle regulators in prostate and human mammary epithelial cell senescence. Canadian Breast Cancer Research – Reasons for Hope National Scientific Conference, Toronto, June 17-19, 1999.

42. Shaw PA, **Slingerland JM**, Sugimoto, A, Covens AL. Prognostic implications of the cell cycle inhibitor $p27^{Kip1}$ in ovarian cancer. United States and Canadian Academy of Pathology 1999 Annual Meeting, San Francisco, CA, March 20-26, 1999.

43. Tsihlias J, Klotz LH, **Slingerland JM.** Growth arrest of LNCaP human prostate cancer cells by high dose dihydrotestosterone: Effect on cell proliferation and changes in the cell cycle regulatory proteins. American Urological Association 1998 Annual Meeting, San Diego, CA, May 29 – June 5, 1998.

44. Sandhu C, Stampfer M, Worland P, **Slingerland JM.** Involvement of Cdc25A in human mammary epithelial cell senescence. Keystone Symposium on the Cell Cycle, Keystone, CO, March 27 – April 2, 1998.

45. Ciarallo S, Stampfer M, **Slingerland JM.** Evidence for a novel inhibitor of p27 in TGF-β resistant human mammary epithelial cells. Keystone Symposium of the Cell Cycle, Keystone, CO, March 27 – April 2, 1998.

46. Tsihlias J, Klotz LH, **Slingerland JM.** High dose dihydrotestosterone treatment of prostate cancer cell line LNCaP: Effect on cell proliferation and changes in the cell cycle regulatory proteins. Annual Urology Research Symposium, University of Toronto, Toronto, February 1998.

47. Tsihlias J, **Slingerland JM.** Growth arrest of LNCaP human prostate cancer cells by high dose dihydrotestosterone: Effect on cell proliferation and changes in the cell cycle regulatory proteins. Keystone Symposium on Molecular and Cellular Biology, Copper Mountain, CO, February 11-26, 1998.

48. Tsihlias J, Kapusta L, Klotz LH, DeBoer G, **Slingerland JM.** The prognostic role of p27, a cyclin-dependent kinase inhibitor, in prostate cancer. Society International d'Urologie 24th Congress, Montreal, PQ, September 1997.

49. Tsihlias J, Kapusta L, Klotz G, DeBoer G, **Slingerland JM.** The prognostic role of p27, a cyclin-dependent kinase inhibitor, in prostate cancer. Canadian Urological Association Annual Meeting, Quebec City, PQ, June 1997.

50. **Slingerland JM**, Sandhu C, Garbe J, Daksis J, Pan C-H, Bhattacharya N, Yaswen P, Koh J, Stampfer MR. TGF-β increases p15 ^{INK4B} protein and p15^{INK4B}/cdk4 complexes and prevents cyclin D1/cdk4 association in human mammary epithelial cells. Cell Cycle Conference, Cold Spring Harbor, NY, May 15-19, 1996.

51. Petrocelli T, Poon R, Drucker DJ, Rosen C, and **Slingerland JM.** UVB radiation induces p21$^{Cip1/WAF1}$ and mediates G1 and S phase checkpoints. The Cell Cycle, Keystone Symposia, Taos, NM, January 1996.

52. Florenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, **Slingerland JM.** IL-6 and TGF-β induced G1-arrest in an early stage human melanoma cell line: Effects on the cell cycle machinery. Cancer and the Cell Cycle, Joint Symposium Swiss Institute for Experimental Cancer Research and American Association for Cancer Research, Lausanne, Switzerland, January 1996.

53. Stampfer M, Garbe J, Chin-Huei P, Rowning B, Yaswen P, **Slingerland JM**, Bodnar A, Villeponteau B. TGF-β resistance to telomerase activity in normal and immortal human mammary epithelial cells in culture. Etiology of Breast and Gynecological Cancer, Austin TX, November 29 – December 2, 1995.

54. Stampfer M, Garbe J, Pan C-H, Alexander D, Reed S, **Slingerland JM.** TGF-β sensitive and resistant human mammary epithelial cells. Keystone Symposia on Molecular and Cellular Biology – Oncogenes: 20 Years Later, Keystone, CO, January 1995.

55. **Slingerland JM**, Reed SI, Pan C-H, Garbe J, Stampfer MR. Mechanisms of TGF-β resistance in human mammary epithelial cells. Cold Spring Harbor Symposium: Molecular Biology of Cancer, Cold Spring Harbor, NY, June 1994.

56. **Slingerland JM**, Reed SI. The effects of TGF-β on G1 cyclin activity in epithelial cells. Presented at the 13th Annual Washington International Spring Symposium, Washington, DC, May 1993.

57. **Slingerland JM**, Benchimol S. Transforming activity of mutant human p53 alleles. Presented at the Fifth Annual p53 Workshop, Princeton, NJ, June 1991.

58. **Slingerland JM**, Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. The Molecular Basis of Human Malignancy, Frederick, MD, June 1990.

59. **Slingerland JM**, Tiberius RG, Bell M, Sackin HD, Jubas K, Matlow A. The impact of student evaluative feedback on the improvement. American Educational Research Association, Annual Meeting, Washington, DC, April 1987.

Grant Award Review Panels

- Doris Duke Charitable Foundation Clinical Scientist Development Award, 2007-2012
- CAMP Study section, Member, NCI, NIH, 2010-present

- CAMP Study section, Ad-Hoc member, NCI, NIH, June 2006
- Dorothy P. Landon-AACR Prize for Translation Cancer Research Committee, 2004-2005
- College of Reviewers, Canada Research Chair Program, 2001- 2003
- Study Section Panel F, National Cancer Institute of Canada, January 1998-2001
- Cancer Genetics Panel, US Army Breast Cancer Research Program, November 1997

TEACHING

Undergraduate Medicine Clinical Teaching, 1993-2002

At the University of Toronto from1993-2002, I taught three hours sessions of clinical bedside teaching to fourth year students in the context of my outpatient breast cancer clinic at the TSRCC. Students are exposed to some of the clinical problems in the management of breast cancer. In addition, I review their skills in history taking and physical examination and provide them with individual feedback.
Clinical Teaching Sessions to Clinical Clerks at SHSC teaching hours included:

6 hrs	1998-99
16 hrs	1999-00
14 hrs	2000-01

Post-Graduate Medical Education

Resident/Fellowship Teaching:

At U of Toronto, (1993-2002), presented one-hour teaching sessions to Oncology or Surgical Fellows and Residents doing rotations in medical oncology in Cell Cycle Regulation and Cancer, have included:

At U of Miami, (2002-2011), provided similar teaching sessions on mechanisms of resistance to antiestrogen therapy and novel targeted therapeutics for breast oncology

6 hrs	1993-2000
2 hrs	2001-2011

Hematology Fellow Teaching Session, Hospital for Sick Children, to hematology fellows was part of their core teaching in basic science.

Topic: *The Cell Cycle and Cancer* 2 hrs April 4, 1997

Graduate Courses

Department of Medical Biophysics, University of Toronto

Basic Science of Oncology Course MBP-1018Y, 1995-2000: two-hour lecture on Cell Cycle Regulation in Mammalian Cells.

Advanced Cell Biology MBP-1001Y, 1999-2001: six-hour session on Cell Cycle Regulation in Mammalian Cells.

Medical Biophysics Graduate Student Seminar Course MBP-1015Y, 1994-2002: weekly seminar required core course in Medical Biophysics. Role: attend the weekly sessions, evaluate student presentations and provide feedback to the students and their supervisors. Time commitment to the course was 1.5 hrs/wk.

Thesis and Dissertation Advisor/Post-doctoral Supervision

Post-doctoral Fellows Supervised

Pierre Morin	January 2010 – September 2011
Yingqiu Xie	October 2009 – August 2011
Katharine Drews-Elger	September 2009 – present
Tonia Hermon	September 2009 – July 2011
Fiona Simpkins (mentored clinician scientist)	July 2008 – present
Natalia Guggisberg	February 2008 – June 2009
Chendong Pan	January 2008 – Jan 2011
Yi Chen	December 2006 – December 2008
Edwin Alvarez	July 2006 – July 2007
Feng Hong	June 2004 – June 2009
Sophie Loiseau	June 2004 – October 2006
Jun Sun	April 2003 – present
Mercedes Porosnicu	November 2002 – July 2003
Wesley Hung	August 2000 – February 2002
Richard Beniston	January 2000 – December 2000
Venkateswaran Subramaniam	December 1999 – November 2000
Rouslan Kotchetkow	November 1999 – June 2001
Mike Connor	August 1999 – July 2004
Jinhwa Lee	September 1998 – October 1999
Sandrine Cariou	February 1997 – July 1999
Wieben Zhang	November 1996 – September 2000
Vivi Ann Florenes	March 1995 – May 1998
Jasmine Daksis	September 1994 – September 1995

Graduate Students Supervised

Kibeom Jang, PhD Student Cancer Biology Program UM Miller School of Medicine	June 2012– present
Minsoon Kim, PhD Student Cancer Biology Program	June 2012– present

UM Miller School of Medicine

Alexandra Besser, MD/PhD Student Cancer Biology Program UM Miller School of Medicine	June 2011 – present
Wen Zhou, PhD Student Dept. of Biochemistry & Molecular Biology UM Miller School of Medicine	August 2009 – present PhD Awarded May 2014
Dekuang Zhao, PhD Student Cancer Biology Program UM Miller School of Medicine	June 2009 – June 2014 PhD Awarded December 2013
Diana Azzam, PhD Student Dept. of Biochemistry & Molecular Biology UM Miller School of Medicine	January 2008 – present PhD Awarded September 2011
Seth Wander, MD/PhD Student Cancer Biology Program UM Miller School of Medicine	August 2008 – September 2011 PhD Awarded September 2011
Thiago da Silva, PhD Student Dept. of Biochemistry & Molecular Biology UM Miller School of Medicine	May 2005 – December 2010 PhD Awarded December 2010
Goldi Kozloski, PhD Student Dept. of Biochemistry & Molecular Biology UM Miller School of Medicine	May 2004 – May 2006 PhD Awarded May 2009
Michelle Larrea, PhD Student Dept. of Biochemistry & Molecular Biology UM Miller School of Medicine	January 2003 – February 2008 PhD Awarded February 2008
Angel Arnaout, MSc Student Institute of Medical Sciences University of Toronto	September 2001 – May 2003 MSc Awarded 2003
Lin Yang, PhD Student Institute of Medical Sciences University of Toronto	September 2001 – September 2002 transferred when I moved to USA
Isabel Chu, PhD Student Department of Medical Biophysics University of Toronto	September 2000 – August 2007 PhD Awarded 2007

Jiyong Liang, PhD Student Department of Medical Biophysics University of Toronto	July 1999 – December 2003 PhD Awarded 2003
Jeffrey Donovan, PhD Student Department of Medical Biophysics University of Toronto	August 1998 – August 2002 PhD Awarded 2002
Teresa Petrocelli, PhD Student Department of Medical Biophysics University of Toronto	February 1995 – August 2001 PhD Awarded 2002
Charanjit Sandhu, PhD Student Department of Medical Biophysics University of Toronto	September 1995 – December 1999 PhD Awarded 2001
Sandra Ciarallo, MSc Student Department of Medical Biophysics University of Toronto	September 1996 – August 1999 MSc Awarded 1999
John Tsihlias, MSc Student Institute of Medical Science University of Toronto	November 1996 – January 1999 MSc Awarded 1999